Pharmaceutical business Amerigen Pharmaceuticals Limited revealed on Thursday the receipt of approval from the US Food and Drug Administration for the Abbreviated New Drug Application (ANDA) for the generic version of Adderall XR in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg.
The company has received the US FDA's NDA approval for the generic version of Shire's Adderall XR (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, extended-release capsules) in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
In conjunction, the company's Amerigen Pharmaceuticals Inc US affiliate is currently selling an authorized generic version of Adderall XR, with a planned launch in the near future.
Additionally, the US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc, based in Lyndhurst, NJ.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules